Intellia Therapeutics developed NTLA-2002, an in vivo therapy for hereditary angioedema, which is delivered intravenously and comprises LNPs containing Cas9 mRNA and sgRNA specific to KLKB1 [108]. Here, KLKB1 is linked to hereditary angioedema.